Isoniazid-related hepatitis

Digestive Diseases

Volumn 15, Issue 6, 1997, Pages 357-367

  Vasudeva, Rajeev ^a   Woods, Bryan ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Hepatitis; Isoniazid; Liver

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

HUMAN; REVIEW; RISK FACTOR; TOXIC HEPATITIS;

ANTITUBERCULAR AGENTS; HEPATITIS, TOXIC; HUMANS; ISONIAZID; RISK FACTORS;

EID: 0031267265     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000171611     Document Type: Article

References (96)

1. Ferebee SH, Mount FW: Tuberculosis morbidity in a controlled trial of prophylactic use of isoniazid among household contacts, Am Rev Rcspir Dis 1962;85:490-510.
2. Ferebce SH, Mount FW, Murray FJ, Livesay VT: A controlled trial of isoniazid prophylaxis in mental institutions, Am Rev Rcspir Dis 1963: 88:161-175.
3. Comstock GW, Ferebee SH, Hammes LM: A controlled trial of community-wide isoniazid prophylaxis in Alaska, Am Rev Rcspir Dis 1967:95:935-943.
4. American Thoracic Society: Untoward reaction to drugs used in the initial chemotherapy of cavitary tuberculosis, Am Rev Respir Dis 1965;91:293-296.
5. Preventative Treatment of Tubercu-losis: A joint statement of the American Thoracic Society, National Tuberculosis and Respiratory Disease Association, and the Centers for Disease Control, Am Rev Respir Dis 1971;104:460-463.
6. Randolph H, Joseph S: Toxic hepatitis with jaundice occurring in a patient treated with isoniazid, JAMA 1953;152:38.
7. Gellis SN, Murphy RV: Hepatitis following isoniazid, Dis Chest 1955: 28:462-464.
8. Gillis S, Texler K: Unusual reactions to antituberculous chemotherapy, Med JAust 1960;ii:99-101.
9. Cohen R, Kaiser MH, Thomson RV: Fatal hepatic necrosis secondary to isoniazid therapy, JAMA 1961;176:877-879.
10. Davies D, Glowinski JJ: Jaundice due to isoniazid, Tubercle 1961:43: 504.
11. Martin CE, Arthand JB: Hepatitis after isoniazid administration, N Engl J Med 1970;282:433-434.
12. Schàrer L, Smith JP: Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid, Ann Intern Med 1969; 71:1113-1120.
13. Martin CE, Arthand JB: Hepatitis after isoniazid administration, N Engl J Med 1970:282:433-434.
14. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MG: Isoniazid-associat-ed hepatitis, Report of an outbreak, Am Rev Respir Dis 1972; 106:357-365.
15. Maddrcy WC, Boitnott JK: Isoniazid hepatitis, Ann Intern Mee 1973; 70:1-12.
16. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR: Isoniazid-associatcd hepatitis in 114 patients, Gastroenterology 1975:69:289-302.
17. Report of the Ad Hoc Committee on Isoniazid and Liver Disease, Centers for Disease Control, Department of Health, Education and Wel-farc, March 17-18, 1971: Isoniazid and Liver Disease, Am Rev Rcspir Dis 1971:104:454-459.
18. Mitchell JR, Long MW, Thorgeirs-son VP, Jollow DJ: Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy, Chest 1975:68: 181-190.
19. Kopanof TDE, Snider DE, Caras GJ: Isoniazid-related hepatitis, A US Public Health Service Cooperative Surveillance Study, Am Rev Respir Dis 1978;117:991-1001.
20. Israel HL: Isoniazid-associated hepatitis, Reconsideration of the indications for administration of isoniazid, Gastroenterology 1975:69:539-542.
21. American Thoracic Society: Control of tuberculosis in the United States, Am Rev Rcspir Dis 1992; 146; 1623-1633.
22. Centers for Disease Control/Advisory Committee for Elimination of Tuberculosis: A strategic plan for the elimination of tuberculosis in the United States, MMWR 1989:38 (suppl 5-3).
23. Centers for Disease Control: Screening for tuberculosis infection in high risk populations and the use of preventive therapy for tuberculosis infection in the United States: Recommendations of the Advisory Committee for Elimination of Tuberculosis, MMWR 1990;39(No, RR-8): 1-12.
24. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgcirsson UP, Timbrcll JA, Snodgrass WR, Nelson SD: Isoniazid liver injury: Clinical spectrum, pathology and probably pathogenesis, Ann Intern Med 1976:84:181-192.
25. Mitchell JR, Jollow DJ: Metabolic activation of drugs to toxic substances, Gastroenterology 1975:68: 92-410.
26. Maddrev WC: Isoniazid-induced liver disease, Semin Liver Dis 1981: 1:129-133.
27. Mitchell JR, Thorgcirsson VP, Black M, Timbrcll JA, Snodgrass WR, Potter WZ, Jollow HR, Keiser HR: Increased incidence of isoniazid hepatitis in rapid acetylators: Possible relation to hydrazine metabolites, Clin Pharmacol Ther 1975:18:70-79.
28. Gronhagen-Riska C, Hcllstroni PE, Froseth B: Predisposing factors in hepatitis induced by isoniazid-ri-fampin treatment of tuberculosis, Am Rev Respir Dis 1978;118:461-466.
29. Gurumurthv P, Krishnamurthy MS, Nazareth O, Parthasarthy R, Sarnia GR, Somasundaram PR, Tripathy SP, Ellard GA: Lack of relationship between hepatic toxicity and acety-lator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis, Am Rev Rcspir Dis 1984; 129:58-61.
30. Martinez-Roig A, Carni J, Llorens-Terol J, de la Torre R, Perieli F: Acetylation phenotype and hepatotoxic-ity in the treatment of tuberculosis in children, Pediatrics 1986:77:912-915.
31. Lee WM: Review article: Drug-induced hepatotoxicity, Aliment Pharmacol Ther 1993;7:477-485.
32. Rapp RS, Campbell RW, Howell JC, Kendig F.L: Isoniazid hepatotoxicity in children, Am Rev Respir Dis 1978;188:794-796.
33. Snider DE, Caras GJ: Isoniazid-as-sociatcd hepatitis deaths: A review of available information, Am Rev Respir Dis 1992:145:494-497.
34. Moulding TS, Rcdckcr AG, Kamal GC: Twenty isoniazid-associalcd deaths in one slate, Am Rev Respir Dis 1989:140:700-705.
35. Comstock GW: Evaluating isonia-zid preventive therapy: The need for more data, Ann Intern Med 1981: 94:817-819.
36. Peretti E, Karlaganis G, Lanterburg BIT Increased urinary excretion of toxic hydrazino metabolites of isoil iazid by slow acetylators, Effect of a slow-rcleasc preparation of isonia-zid, Eur J Clin Pharmacol 1987.33:283-286.
37. Sarma GR, Immanuel C, Kailasam S, Narayana AS, Vcnkatcsan P: Rifampin-induced released of hydrazine from isoniazid, A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin, Am Rev Respir Dis 1986:133:1072-1075.
38. Snider DE, Long MW, Gross FS, Farer LS: Six-month isoniazid-ri-fampin therapy for pulmonary tuberculosis, Report ofa United Stales Health Service Cooperative Trial, Am Rev Respir Dis 1984; 129:573-579.
39. Smith J, Tyrrell WF, Gow A, Allan GW, Lees AW: Hcpatotoxicity in ri-fampin-isoniazid treated patients related to their rate of isoniazid inactivation, Chest 1972:61:587-588.
40. Cross FS, Long MW, Banner AS, Snider DE: Rifampin-isoniazid therapy of alcohol and nonalcoholic tuberculosis patients in a US Public Health Service Cooperative Therapy Trial, Am Rev Respir Dis 1980: 122:349-353.
41. Pcssayre D, Benlata M, Dcgott C, Nouel O, Miguet JP, Rueff B, Ben-hanton JP: Isoniazid-rifampin fulminant hepatitis, A possible consequence of the enhancement of isoniazid hcpatotoxicity by enzyme induction, Gastroenterology 1977:72:284-289.
42. Rapp RS, Campbell RN, Howell JC, Rending EJ Jr.: Isoniazid hcpatotoxicity in children, Am Rev Respir Dis 1978:118:794-796.
43. Centers for Disease Control: Adverse drug reactions among children treated for tuberculosis, MMWR 1980:29:589-591.
44. Steele MA, Burk RF, DesPrcz RM: Toxic hepatitis with isoniazid and rifampin, A meta-analysis, Chest 1991:99:465-471.
45. Kuman A, Misra PK, Mehotra R, Govil YC, Rana GS: Hcpatotoxicity of rifampin and isoniazid, Is it all drug-induced hepatitis? Am Rev Respir Dis 1991,143:1350-1352.
46. Murphy R, Swartz R, Watkins PB: Severe acetaminophen toxicity in a patient receiving isoniazid, Ann Intern Med 1990:113:799-800.
47. Burk RF, Hill RE, Hunt RW, Martin AF: Isoniazid potentiation of acetaminophen hepatotoxicity in the rat and 4-methylpyrazolc inhibition of it, Res Comntun Chcnt Pathol Pharmacol 1990;69:115-118.
48. Bailey WC, Taylor SL, Dascontb HE, Greenberg HB, Ziskind MM: Disturbed hepatic function during isoniazid chemoprophylaxis for tuberculosis, Am Rev Respir Dis 1973;107:523-529.
49. Bailey WC, Weill H, Derouen TA, Ziskind MM, Jackson HA: The effect of isoniazid on transaminase levels, Ann Intcm Med 1974;81: 200-202.
50. Byrd RB, Horn BR, Griggs GA, So lomon DA: Isoniazid chemoprophylaxis: Association with detection and incidence of liver toxicity, Arch I ntcrn Med 1977; 137:1130-1133.
51. Byrd RB, Nelson R, Elliott RC: Isoniazid toxicity: A prospective study in secondary chemoprophy-laxis, JAMA 1972:220:1471-1473
52. Byrd RB, Horn BR, Solomon DA, Griggs GA: Toxic effects of isoniazid in tuberculosis chcmoprophylax-is, JAMA 1979;241:1239-1241.
53. Centers for Disease Control: Severe isoniazid-associated hepatitis - New York, 1991-1993, JAMA 1993:270: 809.
54. Farrell FJ, Keeffe EB, Man KM, Imperial JC, Esquivel CO: Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation, Dig Dis Sei 1994:39:2255-2259.
55. Mitchell I, Wendon J, Fitt S, Williams R: Anti-tuberculous ihcrapy and acute liver failure, Lancet 1995: 345:555-556.
56. Polis MA, Masur H: The problem of tuberculosis with HIV infection: in DeVita VT, Heilman S, Rosenberg SA (eds): AIDS Updates, Philadelphia, Lippincott, 1994, voi 7, pp I-11.
57. Centers for Disease Control: Tuber-culosis and human immunodeficiency virus infection: Recommendations of the Advisory Committee for the Elimination of Tuberculosis, MMWR 1989:38:236-238.
58. Fischi MA, Daikos GL, Ultamchan-dani RB, Poblete RB, Moreno JN, Reyes RR, Boot a AM, Thompson L, Cleary TJ, Oldham SA, Saldana MJ, Lai S: Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug resistant bacilli, Ann Intern Med 1992:117:184-190.
59. Pearson ML, Jercb JA, Frieden TR, Crawford JT, Davis BJ, Dooley SW, Jarvis WR: Nosocomial transmission of multi-drug resistant Mycobacterium tuberculosis, Ann Intern Med 1992;117:257-259.
60. Edlin BR, Tokars JL, Grieco MH, Crawford JT, Williams J, Sordido EM, Ong KR, Kilburn JO, Dooley SW, Castro KG: An outbreak of multidrug-rcsistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome, N Engl J Med 1992,326: 1514-1521.
61. Frieden TR, Sterling T, Pablos-Mcndez A, Kilburn JO, Cauthen GM, Dooley SW: The emergence of drug-resistant tuberculosis in New York City, N Engl J Med 1993;328: 521-526.
62. Ozick LA, Jacob L, Comer GM, Lee TP, Ben-Zvi J, Donclson SS, Felton CP: Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients, Am J Gastroenterol 1995:90: 1978-1980.
63. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hope-well PC: Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection, N Engl J Med 1991;324:289-294.
64. Jones BE, Okaya M, Antoniskis D, Sian S, Wang F, Mercado A, Davidson PT, Barnes PF: A prospective evaluation of antitubcrculosis therapy in patients with HIV infection, Am J Respir Crit Care Med 1994: 150:1499-1402.
65. Barnes PF, Le HQ, Davidson PT: Tuberculosis in patients with HIV infection, Med Clin North Am 1993:77:1369-1390.
66. Pape J W, Jean SS, Ho JI., Hafner A, Johnson WD Jr.: Effect on isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection, Lancet 1993:342:268-272.
67. Malone JL, Paparello SF, Malone JD, Hill HE, Myers JW, Weiss P: Tuberculosis and HIV infection (letter), Lancet 1993:342:677.
68. Aisu T, Raviglione MC, Praag F.V, Eriki P, Narain JP, Barugahare L, Tcmbo G, McFarland D, Engwau FA: Preventative chemotherapy for HIV-associated tuberculosis in Uganda: An operational assessment at a voluntary counselling and testing center, AIDS 1995;9:267-273.
69. DeCock KM, Grant A, Porter JD: Preventive therapy for tuberculosis in HIV-infected persons: International recommendations, research and practice, Lancet 1995:345:833-836.
70. Hopewell PC: Impact of human im-munodcficieny virus infection on the epidemiology, clinical features, management and control of tuberculosis, Clin Infect Dis 1992:15:540-547.
71. Englchard D, Stutman HR, Marks Ml: Interaction of ketoconazole with rifampin and isoniazid, N Engl J Med 1984:311:1681-1683.
72. Lazar JD, Wilner KD: Drug interaction with fluconazole, Rev Infect Dis 1990:12(suppl 3):S327-S333.
73. Alford RH: Antimycobacterial agents; in Mandell GL (ed): Principles and Practice of Infectious Diseases, New York, Churchill Livingstone, 1990, pp 350-360.
74. Antoniskis D, Easley AC, Espina BM, Davidson PT, Barnes PF: Combined toxicity of zidovudine and ant ¡tuberculosis chemotherapy, Am Rev Respir Dis 1992:145:430-434.
75. Gallicano K, Sahai J, Zaror-Bchrcns G, Pakuts A: Effect of antacids in didanosine tablet on bioavailability of isoniazid, Antimierob Agents Chemother 1994:38:894-897.
76. Isoprodian Study Group: Docs isoniazid increase the hepatotoxicilv of the combination prothionamidc-dapsone? Int J Lcpr Other Mvcobact Dis 1992:60:536-541.
77. Salpeter SR: Fatal isoniazid-in-duced hepatitis: Its risk during chemoprophylaxis, West J Med 1993; 159:560-564.
78. Rose DN, Schechter CB, Silver AL: The age threshold for isoniazid chemoprophylaxis, A decision analysis for low-risk tuberculin reactors, JAMA 1986:256:2709-2713.
79. Jordan TJ, Lewit EM, Reichntan LB: Isoniazid preventative therapy of tuberculosis, Decision analysis considering ethnicity and gender, Am Rev Respir Dis 1991; 144:1357-1360.
80. Tsevat J, Taylor WC, Wong TB, Panker SG: Isoniazid for the tuberculin reactor: Take it or leave it, Am Rev Respir Dis 1988:137:215-220.
81. Moudling T: Decision analysis, public health policy and isoniazid chemoprophylaxis for young adult tuberculin skin reactors, Arch Intern Med 1991:151:2101.
82. Jordan TJ, Lewit EM, Montgomery RL, Reichman LB: Isoniazid as preventative therapy in HIV-infected intravenous drug abusers, A decision analysis, JAMA 1991:265: 2987-2991.
83. Iscman MD, Miller B: If a tree falls in the middle of the forest, Isoniazid and hepatitis, Am Rev Respir Dis 1989;140:575-576.
84. Snider DE, Caras GJ, Koplan JP: Preventative therapy with isoniazid, Cost-effectiveness of different durations of therapy, JAMA 1986:255: 1579-1583.
85. Petty TL: Treatment strategies in the prevention of tuberculosis, West J Med 1992:157:463-465.
86. Colicc GL: Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors, Arch Intern Med 1990:150:2517-2522.
87. Israel HL, Gottlieb JE, Maddrey WC: Perspective: Preventative isoniazid therapy and the liver, Chest 1992:101:1298-1301.
88. Tsevat J, Taylor WC, Wong JB, Panker SG: The isoniazid debate (letter: comment), Arch Intern Med 1991:151:2105.
89. Rose DN, Schechter CB, Falis MC, Silver AL: Tuberculosis prevention: Cost-eflectiveness analysis of isoniazid chemoprophylaxis, Am J Prev Med 1988:4:102-109.
90. Stead WW, To T, Harrison RW, Abraham JH: Benefit-risk considerations in preventative treatment for tuberculosis in elderly persons, Ann Intern Med 1987:107:843-845.
91. Noble A: Anti-tuberculous therapy and acute liver failure, Lancet 1995: 345:867.
92. Janes SL, Behrens J: Anti-tubercu-lous therapy and acute liver failure, Lancet 1995:345:867.
93. Durand F, Pessayre D, Fournier M, Belghiti J, Erlingcr S, Bernuau J: Anti-tuberculous therapy and acute liver failure, Lancet 1995:345:1170.
94. McKeon J, Patel AM: Anti-tubercu-lous therapy and acute liver failure, Lancet 1995:345:1170-1171.
95. Caplin M, Thompson N, Hamilton M, McIntyre N, Burroughs A: Anti-tuberculous therapy and acute liver failure, Lancet 1995:345:1170-1171.
96. American Thoracic Society: Treatment of tuberculosis and tuberculosis infection in adults and children, Am J Respir Crit Care Med 1994; 149:1359-1374.